Loading…
Employees: 23
Size Ovid Therapeutics (OVID) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $557M, the 2620th largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.85 on 6 Nov 2026.
Performance Over six months the shares gained 1.8%, against -14.1% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue fell 76.2% over the last twelve months (peer median +9.8%); the operating margin is -3,686.7% (peer median 5.5%).
Valuation It trades at 285.6× enterprise value to sales against a peer median of 5.2× (most expensive of 19).
Capital Return on invested capital runs 50.1 points below its cost of capital (6.3% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.58M | $7.25M | $566,000 | $391,695 | $1.50M |
| Revenue growth | — | +1,181% | +45% | -74% | — |
| Gross profit | $1.47M | $6.95M | -$34,000 | -$1.20M | $121,142 |
| EBITDA | -$58.2M | -$42.1M | -$61.3M | -$57.7M | -$54.2M |
| Net income | -$34.5M | -$17.4M | -$26.4M | -$52.3M | -$54.2M |
| Free cash flow | -$54.8M | -$38.3M | -$56.0M | -$45.8M | -$56.5M |
| Capital expenditure | $0 | $0 | $161,000 | $137,455 | $1.42M |
| Total debt | $12.7M | $13.4M | $14.8M | $46.0M | $16.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OVID | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.8% | -11.6% | 2nd highest of 21 |
| 6-month return | +1.8% | -14.1% | 7th highest of 21 |
| Distance from 52-week high | -8.2% | -32.9% | 2nd highest of 21 |
| Revenue growth (TTM) | -76.2% | +9.8% | 3rd lowest of 20 |
| Operating margin | -3,686.7% | 5.5% | lowest of 19 |
| EV / Sales | 285.6× | 5.2× | most expensive of 19 |
| ROIC minus cost of capital | -50.1 pp | -2.8 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | 5.0× | 5.5% | -1.1% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | 0.8× | 5.0% | +5.0% |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 2.0× | 14.8% | +9.7% |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | 20.8× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |